Resource Logo
NLM AIDSLINE

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.




 

AIDS Res Hum Retroviruses. 1999 May 1;15(7):633-45. Unique Identifier :

A live recombinant canarypox vector expressing HIV-1 gpl20 MN tm/gag/protease LAI (ALVAC-HIV, vCP205) alone or boosted by a p24E-V3 MN synthetic peptide (CLTB-36) was tested in healthy volunteers at low risk for HIV infection for their safety and immunogenicity. Both antigens were well tolerated. ALVAC-HIV (vCP205) induced low levels of neutralizing antibodies against HIV-1 MN in 33% of the volunteers. None of them had detectable neutralizing antibodies against a nonsyncytium-inducing HIV-1 clade B primary isolate (Bx08). After the fourth injection of vCP205, CTL activity was detected in 33% of the volunteers and was directed against Env, Gag, and Pol. This activity was mediated by both CD4+ and CD8+ lymphocytes. On the other hand, the CLTB-36 peptide was poorly immunogenic and induced no neutralizing antibodies or CTLs. Although the ALVAC-HIV (vCP205) and CLTB-36 prime-boost regimen was not optimal, further studies with ALVAC-HIV (vCP205) are warranted because of its clear induction of a cellular immune response and utility as a priming agent for other subunit antigens such as envelope glycoproteins, pseudoparticles, or new peptides.

CLINICAL TRIAL CLINICAL TRIAL, PHASE I JOURNAL ARTICLE RANDOMIZED CONTROLLED TRIAL Adult Amino Acid Sequence Avipoxvirus/GENETICS/*IMMUNOLOGY AIDS Vaccines/*ADVERSE EFFECTS/*IMMUNOLOGY Female Genetic Vectors Human HIV Antibodies/*BIOSYNTHESIS/BLOOD HIV Core Protein p24/CHEMISTRY/IMMUNOLOGY HIV Envelope Protein gp120/ADVERSE EFFECTS/CHEMISTRY/IMMUNOLOGY HIV-1/*IMMUNOLOGY Immunization Schedule Immunization, Secondary Lymphocyte Transformation Male Middle Age Molecular Sequence Data Peptides/CHEMISTRY/CHEMICAL SYNTHESIS/IMMUNOLOGY T-Lymphocytes/IMMUNOLOGY T-Lymphocytes, Cytotoxic/IMMUNOLOGY Vaccines, Synthetic/ADVERSE EFFECTS/IMMUNOLOGY



 




Information in this article was accurate in October 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.